Genzyme Sues Lupin Over Generic Renvela Powder

Law360, New York (July 15, 2010, 3:56 PM EDT) -- Genzyme Corp. has sued India-based Lupin Ltd. and its U.S. affiliate in an effort to block a generic version of kidney disease treatment Renvela in powder form, following up on earlier litigation over the tablet form.

Genzyme filed suit Wednesday in the U.S. District Court for the District of Maryland, where it already has suits pending against Lupin for attempting to make generic tablets of both Renvela and Renagel, a predecessor drug.

Lupin is accused of infringing U.S. Patent Number 5,667,775, which covers both drugs and...
To view the full article, register now.